Exp Clin Endocrinol Diabetes 2017; 125(01): 53-56
DOI: 10.1055/s-0042-117832
Article
© Georg Thieme Verlag KG Stuttgart · New York

Dynamics of Adrenocorticotropin after Application of Metyrapone

Sebastian Noe
1   II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, TU München, Munich
,
Alexander von Werder
1   II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, TU München, Munich
,
Roman Iakoubov
1   II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, TU München, Munich
,
Heike Schneider
2   Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, TU München, Munich
,
Markus Thaler
2   Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, TU München, Munich
,
Peter Luppa
2   Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, TU München, Munich
,
Bruno Neu
1   II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, TU München, Munich
› Author Affiliations
Further Information

Publication History

received 03 July 2016
revised 02 September 2016

accepted 22 September 2016

Publication Date:
17 October 2016 (online)

Abstract

Purpose: To investigate the kinetics of adrenocorticotropin (ACTH) following oral metyrapone administration and describe differences between ACTH-deficient and non-ACTH-deficient subjects.

Methods: Patients from a tertiary endocrine center at a University Hospital in Munich, Germany, were tested for secondary adrenal insufficiency in a regular patient care setting. Metyrapone (Metopirone, HRA Pharma, France) was administered with a dosage of 40 mg/kg bodyweight at 8 a.m. Consecutive levels of ACTH were determined at 0, 60, 120, 180, and 240 min. Patients were categorized according to their need of glucocorticoid substitution in the follow-up phase.

Results: A significant rise in ACTH concentration compared to basal values was found at 60 and 120 min following oral metyrapone administration. ACTH concentrations at 60 and 120 min predicted patients without need for glucocorticoid substitution. ACTH concentrations determined later had no additional benefit.

Conclusion: In contrast to previous reports, we found a significant rise in ACTH concentration as soon as one hour after oral metyrapone administration. ACTH values seem to estimate the pituitary corticotrophic function when correlating results to the further clinical course of subjects. Further studies are needed to investigate this finding as a potential basis for a ACTH-based metyrapone short test protocol.

 
  • References

  • 1 Binder G, Bosk A, Gass M et al. Insulin tolerance test causes hypokalaemia and can provoke cardiac arrhythmias. Hormone research 2004; 62: 84-87
  • 2 Andrioli M, Pecori Giraldi F, Cavagnini F. Isolated corticotrophin deficiency. Pituitary 2006; 9: 289-295
  • 3 Courtney CH, McAllister AS, McCance DR et al. The insulin hypoglycaemia and overnight metyrapone tests in the assessment of the hypothalamic-pituitary-adrenal axis following pituitary surgery. Clinical endocrinology 2000; 53: 309-312
  • 4 Santhanam P, Saleem SF, Saleem TF. Diagnostic predicament of secondary adrenal insufficiency. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2010; 16: 686-691
  • 5 Fiad TM, Kirby JM, Cunningham SK et al. The overnight single-dose metyrapone test is a simple and reliable index of the hypothalamic-pituitary-adrenal axis. Clinical endocrinology 1994; 40: 603-609
  • 6 Liddle GW, Estep HL, Kendall Jr. JW et al. Clinical application of a new test of pituitary reserve. The Journal of clinical endocrinology and metabolism 1959; 19: 875-894
  • 7 Jubiz W, Meikle AW, West CD et al. Single-dose metyrapone test. Arch Intern Med. 1970; 125: 472-474
  • 8 Steiner H, Bahr V, Exner P et al. Pituitary function tests: comparison of ACTH and 11-deoxy-cortisol responses in the metyrapone test and with the insulin hypoglycemia test. Exp Clin Endocrinol. 1994; 102: 33-38
  • 9 Best JD, Alford FP, Donald RA. Evaluation of the three hour metyrapone test in adults. Clinical endocrinology 1980; 13: 69-76
  • 10 Schoneshofer M, Fenner A, Claus M. Suppressive effect of metyrapone on plasma corticotrophin immunoreactivity in normal man. Clinical endocrinology 1983; 18: 363-370
  • 11 Matsuki M, Nishida S, Horino M et al. The discrepancy between plasma 11-deoxycortisol and ACTH concentrations in a single dose metyrapone test in normal men. Acta Endocrinol (Copenh) 1982; 101: 62-65
  • 12 Borm K, Slawik M, Seiler L et al. Is the plasma ACTH concentration a reliable parameter in the insulin tolerance test?. European journal of endocrinology/European Federation of Endocrine Societies 2003; 149: 535-541
  • 13 Kano T, Sugihara H, Sudo M et al. Comparison of pituitary-adrenal responsiveness between insulin tolerance test and growth hormone-releasing peptide-2 test: a pilot study. Peptides 2010; 31: 657-661
  • 14 Kimura T, Shimatsu A, Arimura H et al. Concordant and discordant adrenocorticotropin (ACTH) responses induced by growth hormone-releasing peptide-2 (GHRP-2), corticotropin-releasing hormone (CRH) and insulin-induced hypoglycemia in patients with hypothalamopituitary disorders: evidence for direct ACTH releasing activity of GHRP-2. Endocrine journal 2010; 57: 639-644
  • 15 Hirata Y, Sakamoto N, Matsukura S et al. Plasma levels of beta-MSH and ACTH during acute stresses and metyrapone administration in man. The Journal of clinical endocrinology and metabolism 1975; 41: 1092-1097
  • 16 Dickstein G, Lahav M, Orr ZS. Single-dose metyrapone test at 06.00h: an accurate method for assessment of pituitary-adrenal reserve. Acta Endocrinol (Copenh) 1986; 112: 28-34
  • 17 Giordano R, Picu A, Bonelli L et al. Hypothalamus-pituitary-adrenal axis evaluation in patients with hypothalamo-pituitary disorders: comparison of different provocative tests. Clinical endocrinology 2008; 68: 935-941
  • 18 Arvat E, Di Vito L, Lanfranco F et al. Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study. The Journal of clinical endocrinology and metabolism 2000; 85: 3141-3146
  • 19 Oelkers W. Dose-response aspects in the clinical assessment of the hypothalamo-pituitary-adrenal axis, and the low-dose adrenocorticotropin test. European journal of endocrinology/European Federation of Endocrine Societies 1996; 135: 27-33
  • 20 Berneis K, Staub JJ, Gessler A et al. Combined stimulation of adrenocorticotropin and compound-S by single dose metyrapone test as an outpatient procedure to assess hypothalamic-pituitary-adrenal function. The Journal of clinical endocrinology and metabolism 2002; 87: 5470-5475
  • 21 Hartzband PI, Van Herle AJ, Sorger L et al. Assessment of hypothalamic-pituitary-adrenal (HPA) axis dysfunction: comparison of ACTH stimulation, insulin-hypoglycemia and metyrapone. Journal of endocrinological investigation 1988; 11: 769-776